Harry Keegan
Partner
hkeegan@akingump.com
Areas of Focus
- Capital Markets
- Corporate & Finance
- Corporate Governance
- Mergers & Acquisitions
- Seeding Transactions
- Hedge Funds
- Energy & Infrastructure
- Media, Entertainment & Sports
- Health Care & Life Sciences
- Mining
- Investment Management
- Sovereign & Government Investors
- Renewable Energy
- Joint Ventures & Strategic Alliances
- Energy Transition
- Institutional Investors
- Energy & Natural Resources Funds
- Fund Manager Transactions
- Telecom, Media & Technology
Biography
- Equity capital markets transactions, public takeover transactions (P2Ps) and UK Listing/ Takeover Code matters.
- Public and private cross-border M&A, joint ventures, private equity transactions and corporate reorganisations.
Harry represents parties in international corporate finance transactions. He has considerable experience in advising parties (including issuers, underwriters, selling shareholders, investors, bidders, targets and special committees) on complex equity capital markets transactions, public M&A and corporate governance/ ESG matters. Harry has previously been seconded to two investment banks.
Representative Work
Public-to-private transactions (P2Ps) and UK Takeover Code
- Represented VIP II Blue B.V., a Vitol-affiliated entity, on its $2.3 billion takeover of Vivo Energy Plc, a downstream petroleum company with operations in 23 countries across Africa, dual-listed on the London Stock Exchange and the Johannesburg Stock Exchange.
- Represented the independent directors of Trans-Siberian Gold PLC on its takeover by Horvik Ltd.
- Represented the special committee of LSE-listed IG Seismic Services Plc on its $312.5 million unsolicited takeover by way of MBO.
Equity Capital Markets
- Represented OCM Njord Holdings S.à.r.l. (Oaktree) in a series of transactions including the $250 million partial selldown of its stake in TORM plc, a shipping company and one of the world’s largest owners and operators of product tankers.
- Represented Royalty Pharma Plc, global leader on acquiring pharmaceutical royalties across the life sciences industry, on a series of transactions including its $2.5 billion initial public offering (IPO) and listing on the Nasdaq Global Select Market, complex pre-IPO restructuring and exchange offer.
- Represented a sovereign wealth fund as selling shareholder in the €2.3 billion IPO of a leading investment management firm and on a subsequent secondary selldown by private placement.
- Represented VEON, a global digital and telecoms operator, on a series of transactions including its proposed redomiciliation from Bermuda to the United Kingdom by way of a scheme of arrangement and $2.8 billion dual listing on Euronext Amsterdam and Nasdaq.
EducationB.A., University of Oxford, with honors, 1994
B.A., University of Oxford, with honors, 1994
Bar AdmissionsSolicitor, England and Wales
Solicitor, England and Wales
Recognitions
- IFLR1000 UK, Rising Star, Capital Markets: Equity, M&A, Private Equity, 2019.
- The Legal 500 UK, M&A: Upper Mid-Market and Premium Deals.